First-line treatment strategies for the management of la/mUC: S2 Ep 5 - ESMO 2023: Discussion on 1L LA/mUC

IMPACT Medicom

In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada.
This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl, who discussed the impact of new data from trials on 1L LA/mUC .
Our Guests:
Dr. Thomas Powles: Dr Thomas Powles is a Professor of Genitourinary Oncology and Director of the Barts Cancer Centre at St. Bartholomew's Hospital. He is also the Lead for Solid Tumour Research in London, England.
Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis.
Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers.
Dr. Bernie Eigl: Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers at BC Cancer. He ia alo a Clinical Associate Professor at the University of British Columbia.
This podcast episode was sponsored by Seagen Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com.